Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection

Objective: To compare the efficacy of two- and three-drug regimens for treatin Design: Randomized open-label clinical trial. Setting: Outpatient HIV specialty centers' clinics. Patients: A total of 106 adults with AIDS and MAC bacteremia. Interventions: Patients were treated with clarithromycin 500 mg twice daily and ethambutol 800-1000 mg daily and were randomized to receive clofazimine 100 mg daily or no clofazimine. Main outcome measures: Quantitative blood MAC cultures, symptoms, adverse reactions and survival. Results: Patients randomly assigned to three drugs had significantly higher baseline colony counts of MAC in blood than patients receiving two drugs. The proportion of patients becoming culture-negative was 65% in the two-drug group and 54% in the three-drug group. The median time to negative culture was 58 days for patients in the two-drug group and 63 days for the three-drug group. At the last visit during treatment, the mean reduction in colony forming units/ml of MAC in blood was 1.8 log(10), for the two-drug group and 2.3 log(10) for the three-drug group. Improvement in fever and night sweats was reported by 87 and 89% of the two-drug patients and 84 and 86% of the three-drug patients. During the study, 38% of two-drug patients and 61% of three-drug patients died (P = 0.032), and time to death was shorter in patients treated with three drugs (P = 0,012). In a multivariate analysis, both assignment to clofazimine and high baseline colony counts of MAC bacteremia were significantly associated with death (P < 0.05). Conclusion: The addition of clofazimine to a regimen of clarithromycin and ethambutol for MAC bacteremia in AIDS patients does not contribute to clinical response and is associated with higher mortality.